参附注射液联合西药治疗急性左心衰大鼠NT-proBNP变化的实验研究

刘霖; 王智超; 朱梦莉; 韩瑞萍

doi:10.13201/j.issn.1009-5918.2012.04.005

参附注射液联合西药治疗急性左心衰大鼠NT-proBNP变化的实验研究

- 湖北省武汉市中西医结合医院急诊科(武汉, 430022)
基金项目:
武汉市卫生局科研资助项目（No：WZ11C03）

详细信息

通讯作者: 王智超,E-mail:Whdyyyjzkw@sina.com

中图分类号: R541.6

收稿日期: 2012-04-23

The observation of NT-proBNP in acute left ventricular failure ratstreated with Shenfu injection and medicine

- Department of Emergency, Wuhan Traditional Chinese Medicine and Western Medicine Hospital, Wuhan, 430022, China

More Information

Corresponding author: WANG Zhichao, E-mail: Whdyyyjzkw@sina.com

Received Date: 23 April 2012

摘要

摘要: 目的：探索中药参附注射液治疗急性左心衰大鼠疗效对心力衰竭（心衰）指标NT-proBNP的影响。方法：采用急性左心衰大鼠模型，观察单用西药和参附注射液联合西药治疗前后15 min、30 min、60 min和24 h小时大鼠NT-proBNP、左室收缩末期压（LVESP）、左室内压最大上升速率（dp/dtmax）的变化。结果：参附注射液联合西药治疗急性左心衰大鼠前后30 min NT-proBNP的变化具有统计学意义，联合治疗组优于单纯参附注射液组或单纯西药治疗组。结论：参附注射液对心肌细胞有正性肌力作用，NT-proBNP作为临床中药疗效观察的敏感指标应广泛应用于急性心衰治疗。
- 参附注射液 /
- 急性左心衰 /
- NT-proBNP
Abstract: Objective: To explore the efficacy of NT-proBNP of acute left ventricular failure rats with the treatment of Chinese medicine Shenfu injection.Method: The group of rat model in acute left heart failure, observed the treatment indicators (NT-proBNP, LVESP, dp/dtmax) in sham operation group,separate Chinese medicine, separate Western medicine and combined group in 15 minutes, 30 minutes, 60 minutes and 24 hours.Result: NT-proBNP is statistically significant in the group of 30 minutes treatment of Shenfu injection combined Western medicine rates with acute left ventricular failures. The efficacy of combination therapy group is better than the separate Shenfu injection group and separate Western medicine group.Conclusion: The Shenfu injection has positive inotropic effect on myocardial cells. NT-proBNP as a sensitive indicator of the observation in the clinical traditional Chinese medicines and widely used in the observation the efficacy of acute heart failure.
- Chinese medicine Shenfu injection /
- acute left heart failure /
- NT-proBNP

HTML全文

参考文献(9)

[1]	中华人民共和国卫生部.中药新药临床研究指导原则[M].南京:南京中医药大学出版社,1993:57-60.
[2]	郑世营,张晓膺,李虹,等.参附注射液对心肌细胞缺氧及缺氧/复氧时Fas/Fasl表达的影响[J].中国急救医学,2005,12,25(12):893-895.
[3]	OUANES I, JALLOUL F,AYED S,et al.N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction[J].J Respirology,2012,2:305-322.
[4]	WONG G C,AYAS N T.Clinical approaches to the diagnosis of acute heart failure[J].J Curr Opin Cardiol,2007,22:207-213.
[5]	DE DENUS S,LAVOIE J,DUCHARME A,et al.Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction[J].J Can J Cardiol,2012,28:62-68.
[6]	AMODIO G,ANTONELLI G,DI SERIO F.Cardiac biomarkers in acute coronary syndromes:a review[J].J Curr Vasc Pharmacol,2010,8:388-393.
[7]	TAMURA N,OGAWA Y,CHUSHO H.Cardiac fibrosis in mice lacking brain natriuretic peptide[J].J Proc Natl Acad Sci USA,2000,97:4239-4244.
[8]	SELVAIS P L,DONCKIER J E,ROBERT A.Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure:influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation[J].Eur J Clin Invest,1998,28:636-642.
[9]	NACB Writing Group,WU A H,JAFFE A S,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure[J].J Clin Chem,2007,53:2086-2096.